SS-31

SS-31 is a mitochondria-targeted peptide used primarily for mitochondrial health, anti-aging, and muscle performance. While clinical trials have investigated its use in reperfusion injury, the broader evidence base for other indications remains thin and largely exploratory. Community users typically run 5 mg daily, whereas clinician-led protocols favor a more conservative range of 100 µg to 1 mg daily over 8 to 12-week cycles. Users occasionally report changes in sleep patterns and dream intensity, though injection-site reactions and other common peptide-related side effects have not been a consistent theme. Access is limited, as no insurance pathway exists outside of specific reperfusion injury applications.

Half-life~4 h

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsAnecdotalEfficacyAnecdotalSideEffectsPrice3.82.81.13.62.83.0

Research Evidence

Evidence shape

SS-31 holds a moderate evidence tier, supported by 28 registered trials spanning 21 distinct indications, including heart failure, Barth syndrome, and reperfusion injury. While the research includes eight blinded trials with results and reaches Phase 3 clinical depth, the vast majority of these indications remain thin or exploratory, with only ten trials currently featuring posted results. This indicates a significant long-tail of research that has not yet scaled, leaving most clinical applications supported by single-trial data rather than robust, multi-study consensus.

Depthhow much
28 registered trials
21 completed · 10 with posted results · 3 recruiting / active · combined n=584
Breadthhow many areas
21 indications mapped
1 with results · 18 thin / exploratory · 1 animal-only · 15 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
8 blinded with results · 2 distinct sponsors · AE rows aggregated from 6 trials · 10 linked publications on registered trials
Breadth and depth43 rows captured
Human
direct clinical signal
28
Animal
translational support
12
In vitro
mechanistic support
3
HighMediumLow

Anecdotal efficacy

SS-31 side effects

Clinical research side effects

Anecdotal side effects

Price

Full buying guide →
1
Uther
unknown
1000 mg×10
$550.00
$0.55/mg
2
Saiyan Med
US
500 mg×10
$368.00
$0.74/mg
3
123 Peptides
--
50 mg
$40.00
$0.8/mg
4
Bio Hack London
GB
100 mg
$87.23
$0.872/mg
5
Chimera Peptides
CN
500 mg×10
$449.00
$0.9/mg
6
High Purity Peptides
Hong Kong
100 mg×10
$90.00
$0.9/mg

price offers can be sorted by column · 23 out-of-stock offers not shown

1-6 of 212

SS-31 dosing & protocol

How SS-31 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 21
Typical dose
30 mg10 mg – 40 mg
typical
0
10 mg
20 mg
30 mg
40 mg
distribution of 8 reported doses · darker = more
Frequency
daily
Route
subQ

Subcutaneous doses across trials span 0.01–0.25 mg/kg by weight or fixed amounts from 10–20 mg, with one trial running 20 mg daily for up to eight days; no cycling data appears in the trial record.

21 sources
Clinician practice
Doctor & published-protocol guidance · n = 1
Starting dose
100 µg100 µg – 1 mg
start
0
10 mg
20 mg
30 mg
40 mg
distribution of 3 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
daily
Route
subQ

Clinician practice typically uses 1 mg of SS‑31 subcutaneously each day, though reported doses range from 0.1 mg to 1 mg daily without a specified cycling schedule.

1 source
Anecdotal
Community-reported real-world use · n = 42
Typical dose
5 mg300 µg – 40 mg
typical
0
10 mg
20 mg
30 mg
40 mg
distribution of 46 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
mostly daily
Route
subQ
Cycle
~12-week cycle · 2 reports

Most users take SS‑31 subcutaneously once a day, typically around 2 mg (range 300 µg–40 mg); a smaller number dose twice weekly, weekly, or do not specify a schedule, and only two reports mention a ~12‑week cycle.

42 sources

Regulatory safety notes

Warnings and precautions
  • • Benzyl alcohol toxicity : Do not use in neonates.
Contraindications
  • • Serious hypersensitivity to elamipretide or any of the excipients in FORZINITY [see Warnings and Precautions (5.2) ]. Serious hypersensitivity to any of the ingredients (4 , 5.2)

Related peptides

MOTS-cHumaninGlutathioneSLU-PP-332NAD+